WT or +shSHP2 & SHP2 E76K ). Then doxycycline-treated cells were treated with DMSO or SHP099 at indicated concentrations for either 15 min or 2 h. Cell lysates were collected and SHP2 and p-ERK levels were determined by immunoblotting. (C) Detroit 562 cells were first treated with DMSO, SHP394 at indicated concentrations, or 0.5 µM erlotinib for 15 min. Then either PBS or 100 ng/ml EGF was added into medium in each treatment group as indicated and incubated for another 15 min. Cell lysates were collected and p-ERK levels were determined by immunoblotting. (D) Immunoblot of p-ERK and tubulin in KYSE-520 cells treated with NSC-87877 or IIB-08 at indicated concentrations respectively for either 15 min or 2 h. (E) Anti-proliferative effects of SHP099 at the indicated concentrations in a 6-day cell proliferation assay with SNU-398 (mean percentages of cell viability are shown, error bars, SD; n = 3) and immunoblot of p-ERK and tubulin in SNU-398 cells treated with 0.5 µM BGJ398, 10 µM SHP099, or 0.1 µM trametinib for 2 h. 
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